Boxplot of the acoustic parameters of <i>Scinax pachycrus</i> in response to wind farm noise. The graphs show that calling males found in the ponds of the most intense noise classe... by Rogério Ferreira de Oliveira (11133750)

Subjects:

Decoding the Structure–Property–Function Relationships in Covalent Organic Frameworks for Sustainable Battery Design by Tarek M. Madkour (4921354)

Subjects:

Data sample demographics. Note that AP refers to anti-psychotic medication, and AD refers to anti-depressive medication. Thus, AP and AD in this table refer to the percentage of pa... by Eloy Geenjaar (21533195)

Subjects:

Graphs showing the temporal effects of temperature at the four different positions during a drilling sequence with guide drilling in two steps and final widening drilling (MIPS) an... by Marsel Ganeyev (21453399)

Subjects:

Microstructure of various samples: (a) UT, (b) SP1, (c) SP2, and (d) SP3. by Huashen Guan (20454677)

Subjects:

Error analysis. (a) Location-1 loading. (b) Location-2 loading. by Changxi Shan (22493205)

Subjects:

BPCA ratios and proxies evaluated in this study. The variable <i>n</i> in the equation for the Average CAS refers to the number of carboxylic acid substitutions (3, 4, 5 or 6). The... by Ivy Notterpek (21368133)

These subfigures show a visualization of the context embeddings for the DSVAE model with LS=2=4,CS=2. The first subfigure from the left shows three patient clusters, the second sub... by Eloy Geenjaar (21533195)

Subjects:

Surface 3D topography (a) UT, (b) SP1, (c) SP2, (d) SP3. by Huashen Guan (20454677)

Subjects:

Friction coefficients of various samples: (a) UT, (b) SP1, (c) SP2, and (d) SP3. by Huashen Guan (20454677)

Subjects:

Contents of chlorophyll a, chlorophyll b (Chl a, Chl b) and carotenoid in <i>D</i>. <i>parva</i> cells under treatment of various concentrations of MeJA and GA3. by Lingru Ruan (18995544)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: